Revlimid for 5q- AML – pro
Several studies looked at the efficacy of Revlimid for AML with 5q-. Unfortunately, highly encouraging results with lenalidomide in del(5q) lower-risk MDS were not repeated in del(5q) AML in the studies that tried it, which is not surprising. These 2 disease states are dissimilar with respect to blast presence, clinical behavior, prognosis, and molecular pathology, as well as clonality triggers.
David P. Steensma and Richard M. Stone. Lenalidomide in AML: Del(5q) or who? July 21, 2011; Blood: 118 (3)
Sekeres MA1, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF.A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul 21;118(3):523-8.
Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117:1828–1833.
Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012;12:341–344.